Metabolism of Inositol Polyphosphates by Malignant Hyperthermia-Susceptible and Control Porcine Skeletal Muscle

  • Paul S. Foster
  • Simon P. Hogan
Conference paper


Malignant hyperthermia-susceptible (MH-susceptible, MHS) skeletal muscle cells have an inherited abnormality in the processes that are intimately involved in excitation-contraction coupling (EC coupling) or myoplasmic Ca2+ regulation [1,2]. MHsusceptible muscle cells have an elevated level of myoplasmic Ca2+, and a rapid and sustained rise in myoplasmic Ca2+ is also central to the etiology of fulminant anesthetic-induced MH. The mechanism of signal transduction across the triadic junction during EC coupling of skeletal muscle is unknown [3]. However, mechanical coupling between highly specialized triadic proteins has been proposed as the primary mechanism for voltage-activated generation of sarcoplasmic reticulum (SR) Ca2+ signals and subsequent construction. The dihydropyridine-sensitive Ca2+ channel (voltage sensor) of the transverse tubule (T-tubule) membrane and the ryanodine receptor or Ca2+ release channel of the SR are key proteins involved in this process [3].


High Pressure Liquid Chromatography Inositol Phosphate Malignant Hyperthermia Soluble Extract Inositol Polyphosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Foster PS (1990) Malignant hyperthermia. Int J Biochem 22: 1217–1222PubMedCrossRefGoogle Scholar
  2. 2.
    MacLennan DM, Philips MS (1992) Malignant hyperthermia. Science 256: 789–794PubMedCrossRefGoogle Scholar
  3. 3.
    Dulhunty A (1992) The voltage-activation of contraction in skeletal muscle. Prog Biophys Mol 57: 181–223CrossRefGoogle Scholar
  4. 4.
    MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk R, Frodis W, Britt BA, Worton RG (1990) Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 343: 559–561PubMedCrossRefGoogle Scholar
  5. 5.
    Fujii J, Otsu K, Zorzato F, de Leon S, Khanna VJ, Weiler J, O’Brien PJ, MacLennan DH (1991) Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 253: 448–451PubMedCrossRefGoogle Scholar
  6. 6.
    Otsu K, Nishida K, Kimura Y, Kuzuya T, Hori M, Kamada T, Tada M (1994) The point mutation Arg615–Cys in the Ca2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia. J Biol Chem 265: 13472–13483Google Scholar
  7. 7.
    Quane KA, Keating KE, Manning BM, Healy JMS, Monsieurs K, Heffron JJA, Lehane M, Heytens L, Krisovic-Horber R, Adnet P, et al (1994) Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis of heterogeneity studies. Hum Mol Genet 3: 471–476PubMedCrossRefGoogle Scholar
  8. 8.
    Fletcher JE, Calvo PA, Rosenberg H (1993) Phenotypes associated with malignant hyperthermia susceptibility in swine genotyped as homozygous or heterozygous for the ryanodine receptor mutation. Br J Anaesth 71: 410–417PubMedCrossRefGoogle Scholar
  9. 9.
    Foster PS, Gesini E, Claudianos C, Hopkinson KC, Denborough MA (1989) Inositol 1,4,5-trisphosphate phosphatase deficiency and malignant hyperpyrexia in swine. Lancet 2: 124–127PubMedCrossRefGoogle Scholar
  10. 10.
    Lopez JR, Perez C, Alfonzo M, Cordovez G, Linares N, Allen PD (1993) Changes in intracellular Ca2+ concenration induced by inositol 1,4,5-trisphoshate in human malignant hyperthermia skeletal muscle. Biophys (Life Sci Adv) 12: 131–140Google Scholar
  11. 11.
    Scholz J, Troll U, Schulte AE, Hartung E, Patten M, Sandig P, Schmitz W (1991) Inositol-1,4,5-trisphosphate and malignant hyperthermia. Lancet 337: 1361–1362PubMedCrossRefGoogle Scholar
  12. 12.
    Berridge MJ (1993) Inositol trisphosphate and calcium signalling. Nature 361: 315–325PubMedCrossRefGoogle Scholar
  13. 13.
    Berridge MJ, Irvine RF (1989) Inositol phosphates and cell signalling. Nature 341: 197–205PubMedCrossRefGoogle Scholar
  14. 14.
    Foster PS (1994) The role of phosphoinsositide metabolism in Ca2+ signalling of skeletal muscle cells. Int J Biochem 26: 449–468PubMedCrossRefGoogle Scholar
  15. 15.
    Foster PS, Hogan SP, Hansbro PM, O’brien R, Potter BVL, Ozaki S, Denborough MA (1994) The metabolism of D-myo-inositol 1,4,5-trisphosphate and n-myo-inositol 1,3,4,5-tetrakisphosphate by porcine skeletal muscle. Eur J Biochem 222: 955–964PubMedCrossRefGoogle Scholar
  16. 16.
    Mennati FS, Oliver KG, Putney JW Jr, Shears SB (1993) Inositol phosphates and cell signaling: new views of InsP5 and InsP. Trends Biol Sci 18: 53–56CrossRefGoogle Scholar
  17. 17.
    Hansbro PM, Foster PS, Hogan SP, Ozaki S, Denborough MA (1994) Purification and characterization of D-myo-inositol (1,4,5)/(1,3,4,5)-polyphosphate 5-phosphatase from skeletal muscle. Arch Biochem Biophys 311: 47–54PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • Paul S. Foster
    • 1
  • Simon P. Hogan
    • 1
  1. 1.Division of Biochemistry and Molecular Biology, The John Curtin School of Medical ResearchAustralian National UniversityCanberraAustralia

Personalised recommendations